A groundbreaking study has revealed that GLP-1 receptor agonists—including popular weight-loss and diabetes drugs like ...

Healthcare professionals are calling for a fundamental shift in public perception around medically supervised weight loss ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study.People with type 2 diabetes and obesity who are taking the drugs are also less likely to die ...

New research suggests that semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy, might protect against dementia. More than 6 million Americans are diagnosed with dementia each ...

WEIGHT loss jabs could boost men’s sex lives, a study suggests. Research found injections like Wegovy and Mounjaro can raise ...

Semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy, might also double as a brain booster. Research out today describes a link between semaglutide use and a reduced ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy. These medications mimic the GLP-1 hormone, which helps control insulin ...

Researchers analyzed 130,000 U.S. diabetes patients, including about 20,000 taking semaglutide, known by the brand name Ozempic for diabetes, or Wegovy for weight loss.

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for Alzheimer’s disease, a new study shows.